ENSC: רווח למניה בשנים עשר החודשים האחרונים Ensysce Biosciences Inc.

Patents for the MPAR platform provide Ensysce Biosciences (ENSC) with significant market power and margin potential. However, regulatory pressure and the expansion of new non-opioid analgesics are intensifying competition. The current trailing twelve-month net income per share clearly confirms these challenges, with the metric standing at -2.74. The absence of a stable cash flow leaves the company's financial position dependent on previously raised investments.

The diversification of the Ensysce Biosciences (ENSC) pipeline for opioid overdose protection directly impacts the business's financial stability. This indicator calculates the net income allocated per share over a rolling year, excluding the impact of security issuance. The metric allows for an assessment of the real return on capital without accounting for shareholder dilution. Analyzing the dynamics helps identify revenue stagnation in a timely manner. The current rolling year net income per share visualizes these trends.